• HA-LNP PTEN mRNA for Melanoma Immunotherapy

  2026-08-26

  A 2026 Journal of Controlled Release study developed a PEG-free hyaluronate lipid nanoparticle for topical delivery of PTEN mRNA into melanoma. The platform combined HA-DMG-mediated skin penetration and CD44 targeting with localized PTEN restoration, immunogenic cell death, tumor growth inhibition, and immune activation in preclinical models.

• Trilaurin: A Digestion-Aware Lipid Design Framework

  2026-08-26

  Trilaurin, also known as Glycerol Tridodecanoate, is more than a hydrophobic excipient: its digestion behavior can determine peptide release and proteolytic protection. This article presents an assay-first framework for selecting, testing, and translating trilaurin-based systems across oral delivery and biocatalysis.

• Gepotidacin (GSK2140944): Mechanism & PK

  2026-08-25

  Gepotidacin, also known as GSK2140944, is a first-in-class bacterial type II topoisomerase inhibitor that blocks DNA replication through a mechanism distinct from fluoroquinolones. Its phase I pharmacokinetic profile supports controlled antibacterial research workflows, while assay potency, formulation, and clinical translation must remain clearly separated.

• Kidney-Targeted mRNA Nanoparticles: Loading Study

  2026-08-25

  This 2024 Pace University dissertation examines how excipient selection can address saturation in mRNA loading onto polymeric mesoscale nanoparticles intended for kidney-oriented delivery. By combining loading, size, cytotoxicity, uptake, expression, and pharmacokinetic assessments, the study presents a formulation-screening framework rather than a single validated therapeutic formulation.

• Forsythoside E in New Phenylethanoid Glycosides

  2026-08-24

  The reference study expanded the phytochemical profile of Forsythia suspensa fruits by isolating three previously unreported caffeoyl phenylethanoid glycosides and identifying six known compounds, including Forsythoside E. Its main contribution is rigorous structure elucidation rather than biological target validation, providing a chemical foundation for later work on phenylethanoid glycosides and immunometabolic mechanisms.

• Sulfo-Cy5 NHS Ester for Immune Imaging

  2026-08-24

  Sulfo-Cy5 NHS ester enables bright, aqueous-phase labeling of proteins and ligands that are vulnerable to organic solvents. This article turns the reagent into a practical workflow for tracking immune-cell uptake, including cellular imaging of VLA-4, while separating fluorescence localization from claims about nanostructure-driven immune mechanisms.

• AM 281 and the CB1–CREB–GLT-1 Axis

  2026-08-23

  AM 281 provides a pharmacological route to interrogate how CB1 cannabinoid receptor activity connects endocannabinoid tone with astrocytic GLT-1, CREB signaling, neuronal survival, and cognition. Building on a 2025 traumatic brain injury study, this thought-leadership article outlines the mechanistic rationale, study-design priorities, translational limitations, and strategic opportunities for memory impairment research and morphine withdrawal cognitive studies.

• GI 254023X: Precision ADAM10 Inhibition

  2026-08-22

  GI 254023X offers translational researchers a selective ADAM10 inhibitor for connecting sheddase activity with Notch1 signaling, Jurkat-cell phenotypes, endothelial barrier protection, and vascular integrity. This thought-leadership perspective places the compound within a disciplined evidence framework, using partial BACE inhibition findings to highlight why exposure, selectivity, and functional endpoints must be interpreted together.

• Moesin as a Biomarker of Endothelial Injury in Sepsis

  2026-08-22

  The reference study identifies circulating moesin as a biomarker associated with sepsis severity and links it mechanistically to endothelial hyperpermeability through ROCK1/MLC and NF-κB signaling. Its combination of patient samples, mouse sepsis models, and HMEC experiments provides a useful framework for distinguishing biomarker association from endothelial injury mechanisms.

• Neuromedin S (rat): Protocol and QC Guide

  2026-08-20

  Neuromedin S (rat) provides a defined peptide agonist for controlled neuromedin U receptor signaling studies in rat-relevant in vitro and ex vivo workflows. It should be handled as a research reagent, not used for diagnostic, therapeutic, clinical, or unsupported cross-species applications.

• LDH Cytotoxicity Assay Kit for Nanomaterial Safety

  2026-08-20

  Discover how the LDH Cytotoxicity Assay Kit supports rigorous cell cytotoxicity measurement in magnetite–cellulose nanocrystal research. This guide connects membrane-integrity data with surface chemistry, magnetic hyperthermia, and orthogonal death-pathway validation.

• Brefeldin A: ER Stress Workflow Guide

  2026-08-19

  Brefeldin A (BFA) provides a direct way to perturb ER-to-Golgi trafficking while monitoring ER stress, secretion, cytoskeletal remodeling, and apoptosis in the same experimental system. This guide translates that mechanism into practical workflows for cancer, protein transport, and hypothesis-generating endothelial injury studies.

• Cy5 amine (non-sulfonated): Protocol Guide

  2026-08-19

  Cy5 amine (non-sulfonated), SKU A8143, provides a primary amine for covalent attachment of a bright near-infrared cyanine dye to activated labeling partners. Its water-insoluble profile requires dissolution in DMSO or ethanol before transfer into compatible biomolecule-labeling workflows; it is not intended for direct aqueous labeling, diagnostic use, or medical applications.

• Trilaurin: Practical Formulation and QC Guide

  2026-08-18

  Trilaurin (Glycerol Tridodecanoate) is a water-insoluble, long-chain triacylglycerol used as a lipid excipient, formulation component, and biocatalytic synthesis substrate. This guide covers solvent selection, handling, formulation controls, and assay design while defining where dossier-level application information should not be treated as a validated protocol.

• Mycophenolic Acid: Metabolic Control in Immune Assays

  2026-08-18

  A translational perspective on how Mycophenolic acid, a dehydrogenase inhibitor, can sharpen whole-blood immunometabolism studies by connecting nucleotide biosynthesis with cytokine response, assay design, and decision-making beyond conventional product-page claims.

8126 records 1/542 page Next 12345 下5页 Last page